INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
DN

Dubois-Stringfellow Nathalie

SVP-CHIEF DEVELOPMENT OFFICERCIK 0001947007

EDGAR filingsOpen in network
Disclosed transactions6
Buys / sells0 / 1
Max Insider Score41
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$703
4,036 sh
May 25, 2026May 27, 2026
traded May 25, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    SANGAMO THERAPEUTICS, INCSVP-CHIEF DEVELOPMENT OFFICER · Nov 26, 2025
41
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Open-market sale
SELL
$89K
345.9K sh
Apr 21, 2026
Apr 23, 2026
traded Apr 21, 2026
+2d
SEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$975
2,063 sh
Feb 24, 2026Feb 26, 2026
traded Feb 24, 2026
+2dSEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$5,806
12.4K sh
Feb 25, 2026Feb 26, 2026
traded Feb 25, 2026
+1dSEC FORM 4

Evidence

13
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$15K
36.7K sh
Jan 22, 2026Jan 26, 2026
traded Jan 22, 2026
+4dSEC FORM 4

Evidence

9
DN
Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER
SGMOSANGAMO THERAPEUTICS, INC
Tax withholding
F$1,060
2,544 sh
Nov 24, 2025Nov 26, 2025
traded Nov 24, 2025
+2dSEC FORM 4

Evidence